Investment in development of antiviral drug to Dengue

25 / 02 / 19

Every year about 400 million people worldwide become ill because of the Dengue virus. At Protinhi Therapeutics, a Life Sciences company that is located on Novio Tech Campus, drugs are being developed that fight viruses like Zika and Dengue. Recently they received investments from Oost NL, MSB Isala and investor Frans van Duikeren, to work on their Proof of Concept.

Investment in development of antiviral drug to Dengue

In the media
25 / 02 / 19

Every year about 400 million people worldwide become ill because of the Dengue virus. At Protinhi Therapeutics, a Life Sciences company that is located on Novio Tech Campus, drugs are being developed that fight viruses like Zika and Dengue. Recently they received investments from Oost NL, MSB Isala and investor Frans van Duikeren, to work on their Proof of Concept.

Viral infections like Dengue and Zika are spread by mosquitos and ticks. At the moment, there is no applicable medication for these diseases on the market. According to the WHO, Dengue was diagnosed in nine countries before 1970, nowadays the amount of countries where Dengue is found lies around 140.

 

Protinhi develops drugs that are supposed to slow down viruses. Bernd van Buuren, director of Protinhi: “The fact that the virus is occurring more often, makes the development of a medicine very urgent. Our method blocks an important enzym of the virus, the protease. With the knowledge and means we’re receiving from Oost NL and MSB Isala, we can further enforce our development program. This is necessary for i.e. ruling out side effects.

 

Protinhi is primarily focussing on Dengue, but also explores possibilities for the drugs in regard to other viral infections. Protinhi started as a spin-off from Radboud University and Erasmus MC and is nowadays located on Novio Tech Campus in Nijmegen.

 

Find more information here!